SEC ownership of Vera Therapeutics, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001831828.

Comparable stake leader

Avoro Capital Advisors LLC

Disclosed value leader

PRICE T ROWE ASSOCIATES INC /MD/

Comparable rows

50/50

Latest evidence

30 Jun 2026

Top shareholders Insider holders Latest transactions

Public ticker: VERA on Nasdaq
Parsed ownership sources: 13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: Avoro Capital Advisors LLC
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: Avoro Capital Advisors LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001831828
Issuer location: Brisbane, CA

Ownership snapshot

Top shareholders of Vera Therapeutics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Avoro Capital Advisors LLC

Disclosed value leader

PRICE T ROWE ASSOCIATES I...

Comparable rows

50/50

Latest evidence

30 Jun 2026

13F 13D/G 3/4/5 Lead comparable stake: 8.9% 13D/G row: Avoro Capital Advisors LLC Showing 1-8 of 50 holder rows.

Quick read

Avoro Capital Advisors LLC leads the comparable SEC ownership view at 8.9%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Avoro Capital Advisors LLC's linked filing trail.

Comparable ownership Top 5

Avoro Capital Advisors LLC 8.9%

PRICE T ROWE ASSOCIATES INC /MD/ 7.7%

BlackRock, Inc. 7.4%

STATE STREET CORP 5.8%

Deep Track Capital, LP 5.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Avoro Capital Advisors LLC	13F 13D/G Company 13F 13D/G	8.9% from 13D/G	$245,612,034 5,723,888 shares	—	30 Jun 2026
PRICE T ROWE ASSOCIATES INC /MD/	13D/G 13F T. Rowe Price Associates, Inc. · Company 13D/G 13F	7.7%	$276,595,072 5,461,988 shares	+$90,918,550	31 Dec 2025
BlackRock, Inc.	13F 13D/G Company 13F 13D/G	7.4% from 13D/G	$246,636,382 5,747,760 shares	—	30 Jun 2026
STATE STREET CORP	13F 13D/G Company · STATE STREET CORPORATION 13F 13D/G	5.8% from 13D/G	$178,024,407 4,148,786 shares	—	30 Jun 2026
Deep Track Capital, LP	13D/G 13F Company 13D/G 13F	5.5%	$176,892,640 3,921,362 shares	$0	04 Mar 2026
James E. Flynn	13D/G Deerfield Mgmt, L.P. 13D/G	5.2%	$75,299,151 3,348,117 shares	$0	06 Jun 2025
VANGUARD GROUP INC	13D/G The Vanguard Group 13D/G	5%	$180,805,107 3,570,401 shares	$0	31 Dec 2025
FMR LLC	13D/G 13F Company 13D/G 13F	4.1%	$146,139,596 2,885,853 shares	$0	31 Dec 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$8,736,145.

Buys

$249,985

Insiders: 1

Sells

$8,986,130

Insiders: 8

Net

-$8,736,145

Shares: -219,673

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 5,882 Shares: 225,555

Window (months)	Buy shares	Sell shares	Buy value	Sell value	Net value
0-3	0	83,250	$0	$3,290,329	-$3,290,329
3-6	0	59,951	$0	$2,392,567	-$2,392,567
6-9	0	33,490	$0	$1,406,041	-$1,406,041
9-12	5,882	48,864	$249,985	$1,897,193	-$1,647,208

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 31 reporting-owner rows connected to Vera Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Patrick G. Enright

Net 12M change

-$8,736,144

Latest report

15 Sep 2026

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Patrick G. Enright	Director	$102,609,021	+$249,985	+0.24%	Mixed	21 May 2026
Commodore Capital LP	10%+ Owner	$79,200,000			Filing P/S	10 Jan 2024
Sofinnova Venture Partners X, L.P.	10%+ Owner	$62,408,808			Mixed	06 Feb 2023
Emster Kurt von	Director	$53,605,062			Mixed	17 May 2021
Abingworth LLP	10%+ Owner	$53,284,158			Mixed	13 May 2021
Carlyle Group Inc.	10%+ Owner	$53,284,158			Mixed	17 Aug 2022
Longitude Prime Partners, LLC	10%+ Owner	$30,857,130			Mixed	06 Feb 2023
Longitude Capital Partners IV, LLC	10%+ Owner	$30,857,130			Mixed	06 Feb 2023
Marshall Fordyce	PRESIDENT AND CEO, Director	$18,231,379	-$6,393,474	-26%	Mixed	15 Sep 2026
Beth C. Seidenberg	Director	$6,715,972			Mixed	21 May 2026
Sean Grant	Chief Financial Officer	$5,019,313	-$207,778	-4%	Mixed	23 Feb 2026
Joseph R. Young	Svp, Finance, Chief Acct Offcr	$3,465,154	-$566,738	-14%	Median	11 Sep 2026
Laurence Matthew Skelton	Chief Commercial Officer	$2,696,122	-$66,419	-2.4%	Filing P/S	23 Feb 2026
Jane Wright-Mitchell	Chief Legal Officer	$2,147,287			Mixed	23 Mar 2026
Robert Brenner	Chief Medical Officer	$2,138,953	-$90,307	-4.1%	Filing P/S	23 Feb 2026
Nancy Lee Boman	Chief Regulatory Officer	$1,930,392			Median	03 Aug 2026
David Lee Johnson	Chief Operating Officer	$1,919,797	-$108,276	-5.3%	Filing P/S	23 Feb 2026
William D. Turner	Chief Regulatory Officer	$1,902,416	-$1,445,639	-43%	Filing P/S	23 Feb 2026
Jason S. Carter	Chief Legal Officer	$1,366,983	-$107,498	-7.3%	Filing P/S	21 Nov 2025
Joanne Curley	Chief Development Officer	$485,316			Mixed	21 Aug 2023

Recent insider transactions for Vera Therapeutics, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
Marshall Fordyce	VERA	Class A Common Stock	Sale	-7.29%	$684,500	$37.00	-18,500	235,244	15 Sep 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Options Exercise	7.86%			18,500	253,744	15 Sep 2026	Direct
Marshall Fordyce	VERA	Stock Option (Right to Buy)	Options Exercise	-3.65%			-18,500	488,801	15 Sep 2026	Direct
Joseph R. Young	VERA	Class A Common Stock	Options Exercise	6.6%			5,000	80,754	11 Sep 2026	Direct
Joseph R. Young	VERA	Stock Option (right to buy)	Options Exercise	-13%			-5,000	33,589	11 Sep 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Sale	-7.29%	$649,642	$35.12	-18,500	235,244	02 Sep 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Options Exercise	7.86%			18,500	253,744	02 Sep 2026	Direct
Marshall Fordyce	VERA	Stock Option (Right to Buy)	Options Exercise	-3.52%			-18,500	507,301	02 Sep 2026	Direct
Nancy Lee Boman	VERA	Class A Common Stock	Award				44,987	44,987	03 Aug 2026	Direct
Nancy Lee Boman	VERA	Stock Option (right to buy)	Award				63,011	63,011	03 Aug 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Sale	-16.4%	$1,956,187	$42.30	-46,250	235,244	07 Jul 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Options Exercise	19.7%			46,250	281,494	07 Jul 2026	Direct
Marshall Fordyce	VERA	Stock Option (Right to Buy)	Options Exercise	-8.08%			-46,250	525,801	07 Jul 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Sale	-7.29%	$701,769	$37.93	-18,500	235,244	23 Jun 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Options Exercise	7.86%			18,500	253,744	23 Jun 2026	Direct
Marshall Fordyce	VERA	Stock Option (Right to Buy)	Options Exercise	-3.13%			-18,500	572,051	23 Jun 2026	Direct
Scott W. Morrison	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Andrew Cheng	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Beth C. Seidenberg	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Christy J. Oliger	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
James R. Meyers	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Kimball Hall	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Michael Morrissey	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Patrick G. Enright	VERA	Stock Option (right to buy)	Award				17,084	17,084	21 May 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Sale	-7.29%	$679,747	$36.74	-18,500	235,244	12 May 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Options Exercise	7.86%			18,500	253,744	12 May 2026	Direct
Marshall Fordyce	VERA	Stock Option (Right to Buy)	Options Exercise	-3.04%			-18,500	590,551	12 May 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Sale	-8.89%	$1,011,051	$44.05	-22,951	235,244	14 Apr 2026	Direct
Jane Wright-Mitchell	VERA	Class A Common Stock	Award				42,403	42,403	23 Mar 2026	Direct
Jane Wright-Mitchell	VERA	Stock Option (right to buy)	Award				56,850	56,850	23 Mar 2026	Direct
Joseph R. Young	VERA	Class A Common Stock	Options Exercise	15.2%			10,000	75,754	13 Mar 2026	Direct
Joseph R. Young	VERA	Stock Option (right to buy)	Options Exercise	-20.6%			-10,000	38,589	13 Mar 2026	Direct
Christopher Hite	VERA	Stock Option (right to buy)	Award				24,937	24,937	05 Mar 2026	Direct
Robert Brenner	VERA	Class A Common Stock	Sale	-4.05%	$90,307	$41.98	-2,151	50,947	23 Feb 2026	Direct
Joseph R. Young	VERA	Class A Common Stock	Sale	-4.59%	$130,864	$41.98	-3,117	64,722	23 Feb 2026	Direct
Sean Grant	VERA	Class A Common Stock	Sale	-4.15%	$207,778	$41.98	-4,949	114,181	23 Feb 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Sale	-6.18%	$710,578	$41.98	-16,925	257,163	23 Feb 2026	Direct
David Lee Johnson	VERA	Class A Common Stock	Sale	-5.34%	$108,276	$41.98	-2,579	45,727	23 Feb 2026	Direct
William D. Turner	VERA	Class A Common Stock	Sale	-4.6%	$91,819	$41.98	-2,187	45,313	23 Feb 2026	Direct
Laurence Matthew Skelton	VERA	Class A Common Stock	Sale	-2.4%	$66,419	$41.98	-1,582	64,218	23 Feb 2026	Direct
Joseph R. Young	VERA	Class A Common Stock	Award	17.3%			10,000	67,839	04 Feb 2026	Direct
Joseph R. Young	VERA	Stock Option (right to buy)	Award				20,000	20,000	04 Feb 2026	Direct
Marshall Fordyce	VERA	Class A Common Stock	Award	33.5%			68,800	274,088	04 Feb 2026	Direct
Marshall Fordyce	VERA	Stock Option (right to buy)	Award				137,500	137,500	04 Feb 2026	Direct
Sean Grant	VERA	Class A Common Stock	Award	26.6%			25,000	119,130	04 Feb 2026	Direct
Sean Grant	VERA	Stock Option (right to buy)	Award				50,000	50,000	04 Feb 2026	Direct
Laurence Matthew Skelton	VERA	Class A Common Stock	Award	43.7%			20,000	65,800	04 Feb 2026	Direct
Laurence Matthew Skelton	VERA	Stock Option (right to buy)	Award				40,000	40,000	04 Feb 2026	Direct
William D. Turner	VERA	Class A Common Stock	Award	111.1%			25,000	47,500	04 Feb 2026	Direct
William D. Turner	VERA	Stock Option (right to buy)	Award				50,000	50,000	04 Feb 2026	Direct

^* marks a reported price that did not pass the local price check.